ASTRAZENECA PLC Quarterly Research And Development Expense in USD from Q2 2017 to Q2 2024

Taxonomy & unit
ifrs-full: USD
Summary
Astrazeneca Plc annual/quarterly Research And Development Expense history and growth rate from Q2 2017 to Q2 2024.
  • Astrazeneca Plc Research And Development Expense for the quarter ending June 30, 2024 was $3.01B, a 12.8% increase year-over-year.
  • Astrazeneca Plc annual Research And Development Expense for 2024 was $13.6B, a 24.2% increase from 2023.
  • Astrazeneca Plc annual Research And Development Expense for 2023 was $10.9B, a 12% increase from 2022.
  • Astrazeneca Plc annual Research And Development Expense for 2022 was $9.76B, a 0.27% increase from 2021.
Research And Development Expense, Quarterly (USD)
Research And Development Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $3.01B +$341M +12.8% Apr 1, 2024 Jun 30, 2024 6-K 2024-07-25
Q2 2023 $2.67B +$121M +4.75% Apr 1, 2023 Jun 30, 2023 6-K 2024-07-25
Q2 2022 $2.55B +$717M +39.2% Apr 1, 2022 Jun 30, 2022 6-K 2023-07-28
Q2 2021 $1.83B +$440M +31.7% Apr 1, 2021 Jun 30, 2021 6-K 2022-07-29
Q2 2020 $1.39B +$33M +2.43% Apr 1, 2020 Jun 30, 2020 6-K/A 2021-07-30
Q2 2019 $1.36B -$6M -0.44% Apr 1, 2019 Jun 30, 2019 6-K/A 2020-07-31
Q2 2018 $1.36B +$13M +0.96% Apr 1, 2018 Jun 30, 2018 6-K 2019-07-25
Q2 2017 $1.35B Apr 1, 2017 Jun 30, 2017 6-K 2018-07-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.